HK1252316A1 - IL-1β抗體的用途 - Google Patents

IL-1β抗體的用途

Info

Publication number: HK1252316A1
Authority: HK; Hong Kong
Prior art keywords: 1beta antibodies; 1beta; antibodies
Prior art date: 2005-10-26

Application number

HK18111596A

Other languages

English (en)

Inventor

Phil Lowe

Hermann Gram

Thomas Jung

Timothy Wright

Trevor Mundel

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-26

Filing date

2018-09-10

Publication date

2019-05-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1252316(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-09-10 Application filed by Novartis Ag filed Critical Novartis Ag

2019-05-24 Publication of HK1252316A1 publication Critical patent/HK1252316A1/zh

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Zoology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)

HK18111596A 2005-10-26 2018-09-10 IL-1β抗體的用途 HK1252316A1 (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US73043505P	2005-10-26	2005-10-26
US74212505P	2005-12-02	2005-12-02

Publications (1)

Publication Number	Publication Date
HK1252316A1 true HK1252316A1 (zh)	2019-05-24

Family

ID=37806690

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
HK09100171.2A HK1121041A1 (en)	2005-10-26	2009-01-07	Novel use of anti il-1beta antibodies
HK15105300.7A HK1204767A1 (zh)	2005-10-26	2015-06-03	抗體治療家族性地中海熱
HK18111596A HK1252316A1 (zh)	2005-10-26	2018-09-10	IL-1β抗體的用途

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
HK09100171.2A HK1121041A1 (en)	2005-10-26	2009-01-07	Novel use of anti il-1beta antibodies
HK15105300.7A HK1204767A1 (zh)	2005-10-26	2015-06-03	抗體治療家族性地中海熱

Country Status (29)

Country	Link
US (8)	US8105587B2 (zh)
EP (5)	EP3332807B1 (zh)
JP (4)	JP2009513645A (zh)
KR (3)	KR101518064B1 (zh)
CN (2)	CN102861332A (zh)
AU (1)	AU2006306280B2 (zh)
BR (1)	BRPI0617830B8 (zh)
CA (3)	CA2626214C (zh)
CY (4)	CY1113378T1 (zh)
DK (2)	DK2848258T3 (zh)
ES (3)	ES2662420T3 (zh)
HK (3)	HK1121041A1 (zh)
HU (2)	HUE036973T2 (zh)
IL (4)	IL190545A (zh)
JO (2)	JO2826B1 (zh)
LT (3)	LT2848258T (zh)
LU (2)	LU92326I2 (zh)
MA (1)	MA29919B1 (zh)
NO (2)	NO345888B1 (zh)
NZ (1)	NZ567222A (zh)
PH (2)	PH12013501287A1 (zh)
PL (2)	PL2848258T3 (zh)
PT (2)	PT1940465E (zh)
RU (2)	RU2468817C2 (zh)
SI (2)	SI1940465T1 (zh)
TN (1)	TNSN08189A1 (zh)
TR (1)	TR201802449T4 (zh)
TW (3)	TWI388335B (zh)
WO (1)	WO2007050607A2 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3332807B1 (en)	2005-10-26	2023-02-22	Novartis AG	Use of anti il-1beta antibodies
CA3080328C (en)	2007-05-29	2022-06-21	Novartis Ag	New indications for anti-il-1-beta therapy
AU2012203931B2 (en) *	2007-05-29	2014-04-24	Novartis Ag	New indications for anti-IL-I-beta therapy
EP2293816B1 (en) *	2008-06-06	2012-11-07	XOMA Technology Ltd.	Methods for the treatment of rheumatoid arthritis
EP2196476A1 (en)	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
WO2011032119A1 (en)	2009-09-14	2011-03-17	The Regents Of The University Of Colorado	Modulation of yeast-based immunotherapy products and responses
JP2013507929A (ja) *	2009-10-15	2013-03-07	アボット・ラボラトリーズ	Ｉｌ−１結合蛋白質
PE20130205A1 (es) *	2010-05-14	2013-03-24	Abbvie Inc	Proteinas de union a il-1
SG10201604699VA (en) *	2010-12-21	2016-07-28	Abbvie Inc	Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
CN103649336A (zh)	2011-05-10	2014-03-19	雀巢产品技术援助有限公司	用于个体化治疗管理的疾病活动性表征方法
EP3426775A1 (en)	2016-03-10	2019-01-16	Novartis AG	Chemically modified messenger rna's
CA3064529C (en)	2017-05-31	2021-12-14	Prometheus Biosciences, Inc.	Methods for assessing mucosal healing in crohn's disease patients
UY37758A (es)	2017-06-12	2019-01-31	Novartis Ag	Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (en)	2017-06-22	2018-12-27	Novartis Ag	IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
JP2021523894A (ja)	2018-05-09	2021-09-09	ノバルティスアーゲー	カナキヌマブの使用
WO2020128637A1 (en)	2018-12-21	2020-06-25	Novartis Ag	Use of il-1 binding antibodies in the treatment of a msi-h cancer
EP3897613A1 (en)	2018-12-21	2021-10-27	Novartis AG	Use of il-1beta binding antibodies
EP3898674A1 (en)	2018-12-21	2021-10-27	Novartis AG	Use of il-1beta binding antibodies
BR112021011351A2 (pt)	2018-12-21	2021-11-16	Novartis Ag	Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
TWI793503B (zh) *	2020-01-20	2023-02-21	美商美國禮來大藥廠	抗IL-1β抗體
KR20230109107A (ko) *	2022-01-10	2023-07-19	(주)지아이이노베이션	글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
SG48759A1 (en)	1990-01-12	2002-07-23	Abgenix Inc	Generation of xenogenic antibodies
US5350683A (en)	1990-06-05	1994-09-27	Immunex Corporation	DNA encoding type II interleukin-1 receptors
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en)	1990-08-29	1997-09-10	GenPharm International, Inc.	production and use of transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
WO1995001997A1 (en)	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
EP0690673A4 (en)	1993-12-14	1996-05-29	Univ Pittsburgh	SYSTEMIC GENETIC TREATMENT OF TISSUE DISEASES
US6258823B1 (en)	1996-07-12	2001-07-10	Ariad Pharmaceuticals, Inc.	Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en)	1997-08-08	2001-09-25	Amgen Inc.	Composition and method for treating inflammatory diseases
JP2003500005A (ja)	1999-02-10	2003-01-07	インターリューキンジェネティックスインコーポレイテッド	ＩＬ−１β遺伝子の突然変異に基づく治療および診断
JP2003505361A (ja) *	1999-07-16	2003-02-12	レオ・ファーマ・アクティーゼルスカブ	ＩＬ−１βおよびＴＮＦ−αの抑制剤としてのアミノベンゾフェノン
WO2001014387A1 (en)	1999-08-24	2001-03-01	Ariad Gene Therapeutics, Inc.	28-epirapalogs
GB0001448D0 (en) *	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
EP2241328A1 (en)	2000-05-12	2010-10-20	Immunex Corporation	Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
EP1337527B1 (en)	2000-11-07	2009-10-14	Novartis AG	Indolylmaleimide derivatives as protein kinase c inhibitors
WO2003010282A2 (en) *	2001-07-26	2003-02-06	Eli Lilly And Company	Interleukin-1 beta antibodies
EP1450837A4 (en)	2001-08-07	2006-01-04	Immunex Corp	INTERLEUKIN-1 RECEPTORS IN THE TREATMENT OF DISEASES
ES2385823T3 (es)	2001-12-01	2012-08-01	Iskra Wind Turbines Ltd.	Generador de corriente alterna síncrono que incorpora un mecanismo de frenado
KR200268109Y1 (ko)	2001-12-06	2002-03-15	김정훈	편평형 무정류자 진동모터
EP2407473A3 (en)	2002-02-01	2012-03-21	ARIAD Pharmaceuticals, Inc	Method for producing phosphorus-containing compounds
KR20040094413A (ko)	2002-02-01	2004-11-09	오메로스 코포레이션	연골 분해를 전신 억제하기 위한 조성물 및 방법
KR20040105710A (ko)	2002-02-11	2004-12-16	아르키온 라이프 사이언씨즈 엘엘씨	정제된 사이토킨 억제인자
TWI324064B (en)	2002-04-03	2010-05-01	Novartis Ag	Indolylmaleimide derivatives
NZ540427A (en)	2002-12-09	2008-04-30	Univ Texas	Methods for selectively inhibiting janus tyrosine kinase 3 (Jak3)
EP1590369B1 (en) *	2003-01-24	2016-03-16	Applied Molecular Evolution, Inc.	Human il-1 beta antagonists
GB0303337D0 (en) *	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
WO2005047906A1 (en)	2003-11-10	2005-05-26	Vertex Pharmaceuticals Incorporated	Methods for monitoring il-18
BRPI0506817A (pt)	2004-01-12	2007-05-29	Cytopia Res Pty Ltd	inibidores seletivos de quinase
JP4989456B2 (ja)	2004-02-26	2012-08-01	ベイラーリサーチインスティテュート	関節炎の全身処置のための組成物および方法
US7531570B2 (en)	2004-05-27	2009-05-12	Vertex Pharmaceuticals Incorporated	Treatment of diseases using ICE inhibitors
AU2005249570B2 (en) *	2004-06-04	2011-06-16	Regeneron Pharmaceuticals, Inc.	Methods of using IL-1 antagonists to treat autoinflammatory disease
JP2009501128A (ja)	2005-01-20	2009-01-15	ユニバーシティーオブロチェスター	炎症疾患および炎症障害の研究および処置のための組成物および方法
EP2371967B1 (en)	2005-03-18	2015-06-03	DSM IP Assets B.V.	Production of carotenoids in oleaginous yeast and fungi
PL2163562T3 (pl)	2005-06-21	2014-03-31	Xoma Us Llc	Przeciwciała wiążące IL-1 beta i ich fragmenty
EP3332807B1 (en) *	2005-10-26	2023-02-22	Novartis AG	Use of anti il-1beta antibodies

2006
- 2006-10-24 EP EP17199544.2A patent/EP3332807B1/en active Active
- 2006-10-24 ES ES14191582.7T patent/ES2662420T3/es active Active
- 2006-10-24 NZ NZ567222A patent/NZ567222A/en unknown
- 2006-10-24 LT LTEP14191582.7T patent/LT2848258T/lt unknown
- 2006-10-24 WO PCT/US2006/041479 patent/WO2007050607A2/en active Application Filing
- 2006-10-24 EP EP10181100A patent/EP2332577A1/en not_active Withdrawn
- 2006-10-24 PT PT06826560T patent/PT1940465E/pt unknown
- 2006-10-24 KR KR1020087009981A patent/KR101518064B1/ko active IP Right Grant
- 2006-10-24 US US12/090,490 patent/US8105587B2/en active Active
- 2006-10-24 JP JP2008537878A patent/JP2009513645A/ja not_active Withdrawn
- 2006-10-24 ES ES06826560T patent/ES2389110T3/es active Active
- 2006-10-24 PL PL14191582T patent/PL2848258T3/pl unknown
- 2006-10-24 EP EP23155348.8A patent/EP4218815A3/en active Pending
- 2006-10-24 EP EP14191582.7A patent/EP2848258B1/en active Active
- 2006-10-24 BR BRPI0617830A patent/BRPI0617830B8/pt active IP Right Grant
- 2006-10-24 CN CN2012102904088A patent/CN102861332A/zh active Pending
- 2006-10-24 RU RU2008120625/15A patent/RU2468817C2/ru active
- 2006-10-24 DK DK14191582.7T patent/DK2848258T3/en active
- 2006-10-24 TR TR2018/02449T patent/TR201802449T4/tr unknown
- 2006-10-24 KR KR1020177008682A patent/KR20170038131A/ko not_active Application Discontinuation
- 2006-10-24 HU HUE14191582A patent/HUE036973T2/hu unknown
- 2006-10-24 ES ES17199544T patent/ES2944067T3/es active Active
- 2006-10-24 CA CA2626214A patent/CA2626214C/en active Active
- 2006-10-24 CA CA2963828A patent/CA2963828A1/en not_active Abandoned
- 2006-10-24 SI SI200631412T patent/SI1940465T1/sl unknown
- 2006-10-24 NO NO20200810A patent/NO345888B1/no unknown
- 2006-10-24 PT PT141915827T patent/PT2848258T/pt unknown
- 2006-10-24 CN CN200680039395XA patent/CN101291693B/zh active Active
- 2006-10-24 AU AU2006306280A patent/AU2006306280B2/en active Active
- 2006-10-24 SI SI200632245T patent/SI2848258T1/en unknown
- 2006-10-24 PL PL06826560T patent/PL1940465T3/pl unknown
- 2006-10-24 CA CA2898369A patent/CA2898369C/en active Active
- 2006-10-24 KR KR1020147035512A patent/KR101749388B1/ko active IP Right Grant
- 2006-10-24 DK DK06826560.2T patent/DK1940465T3/da active
- 2006-10-24 EP EP06826560A patent/EP1940465B1/en active Active
- 2006-10-25 TW TW095139438A patent/TWI388335B/zh active
- 2006-10-25 TW TW105103583A patent/TWI626056B/zh active
- 2006-10-25 TW TW101132057A patent/TWI537003B/zh active
- 2006-10-29 JO JO2006387A patent/JO2826B1/en active
2008
- 2008-03-31 IL IL190545A patent/IL190545A/en active IP Right Grant
- 2008-04-23 MA MA30863A patent/MA29919B1/fr unknown
- 2008-04-25 TN TNP2008000189A patent/TNSN08189A1/en unknown
- 2008-05-23 NO NO20082344A patent/NO345140B1/no unknown
2009
- 2009-01-07 HK HK09100171.2A patent/HK1121041A1/xx unknown
2011
- 2011-10-27 US US13/283,165 patent/US8409576B2/en active Active
2012
- 2012-08-06 RU RU2012133522/15A patent/RU2571563C2/ru active
- 2012-09-24 CY CY20121100867T patent/CY1113378T1/el unknown
2013
- 2013-02-26 US US13/777,609 patent/US20130171167A1/en not_active Abandoned
- 2013-03-27 JP JP2013066205A patent/JP6061747B2/ja active Active
- 2013-06-18 PH PH12013501287A patent/PH12013501287A1/en unknown
- 2013-12-05 LU LU92326C patent/LU92326I2/fr unknown
- 2013-12-06 LT LTPA2013026C patent/LTC1940465I2/lt unknown
- 2013-12-13 CY CY2013046C patent/CY2013046I2/el unknown
2014
- 2014-03-16 JO JOP/2014/0120A patent/JOP20140120B1/ar active
2015
- 2015-06-03 HK HK15105300.7A patent/HK1204767A1/zh unknown
- 2015-07-28 US US14/810,556 patent/US9649377B2/en active Active
- 2015-10-02 JP JP2015196708A patent/JP6286403B2/ja active Active
2016
- 2016-05-02 IL IL245387A patent/IL245387B/en active IP Right Grant
2017
- 2017-04-11 US US15/484,459 patent/US20170218063A1/en not_active Abandoned
- 2017-08-04 JP JP2017151327A patent/JP2017206552A/ja active Pending
2018
- 2018-03-12 CY CY20181100301T patent/CY1120018T1/el unknown
- 2018-03-12 US US15/918,136 patent/US20180201674A1/en not_active Abandoned
- 2018-04-26 IL IL258983A patent/IL258983B/en active IP Right Grant
- 2018-06-11 HU HUS1800025C patent/HUS1800025I1/hu unknown
- 2018-06-11 LU LU00078C patent/LUC00078I2/fr unknown
- 2018-06-12 LT LTPA2018506C patent/LTC2848258I2/lt unknown
- 2018-06-12 CY CY2018018C patent/CY2018018I1/el unknown
- 2018-09-10 HK HK18111596A patent/HK1252316A1/zh unknown
2020
- 2020-06-19 US US16/906,118 patent/US20210147533A1/en not_active Abandoned
- 2020-06-23 PH PH12020500559A patent/PH12020500559A1/en unknown
- 2020-09-16 IL IL277406A patent/IL277406A/en unknown
2023
- 2023-02-28 US US18/175,849 patent/US20240083997A1/en active Pending

Also Published As

Publication number	Publication date
IL245387A0 (en)	2016-06-30
US8409576B2 (en)	2013-04-02
CY2018018I2 (el)	2018-12-12
BRPI0617830B1 (pt)	2020-10-20
US20080286266A1 (en)	2008-11-20
PH12013501287B1 (en)	2016-02-01
PH12020500559A1 (en)	2021-06-14
WO2007050607A2 (en)	2007-05-03
BRPI0617830B8 (pt)	2021-05-25
US8105587B2 (en)	2012-01-31
HUS1800025I1 (hu)	2018-07-30
KR20150013834A (ko)	2015-02-05
CA2898369A1 (en)	2007-05-03
AU2006306280A1 (en)	2007-05-03
SI1940465T1 (sl)	2012-10-30
RU2008120625A (ru)	2010-01-20
NO20200810A1 (no)	2008-07-22
PH12013501287A1 (en)	2016-02-01
LU92326I2 (fr)	2014-02-05
US20180201674A1 (en)	2018-07-19
PT1940465E (pt)	2012-10-03
IL258983B (en)	2020-10-29
EP1940465B1 (en)	2012-08-01
MA29919B1 (fr)	2008-11-03
CA2898369C (en)	2017-06-20
TW200803898A (en)	2008-01-16
RU2468817C2 (ru)	2012-12-10
JP6061747B2 (ja)	2017-01-18
JP6286403B2 (ja)	2018-02-28
KR20080059598A (ko)	2008-06-30
CY1113378T1 (el)	2015-11-04
TWI388335B (zh)	2013-03-11
KR101749388B1 (ko)	2017-06-20
JP2017206552A (ja)	2017-11-24
CA2963828A1 (en)	2007-05-03
PL2848258T3 (pl)	2018-06-29
RU2571563C2 (ru)	2015-12-20
ES2944067T3 (es)	2023-06-19
EP3332807A2 (en)	2018-06-13
JP2016020377A (ja)	2016-02-04
US20120039910A1 (en)	2012-02-16
KR101518064B1 (ko)	2015-05-06
PT2848258T (pt)	2018-03-20
CY2013046I1 (el)	2015-11-04
WO2007050607A3 (en)	2007-06-28
US9649377B2 (en)	2017-05-16
CY1120018T1 (el)	2018-12-12
CA2626214C (en)	2016-06-21
IL190545A (en)	2016-09-29
CN101291693A (zh)	2008-10-22
EP4218815A2 (en)	2023-08-02
LU92326I9 (zh)	2019-01-16
CN102861332A (zh)	2013-01-09
US20130171167A1 (en)	2013-07-04
TW201617097A (zh)	2016-05-16
LTC1940465I2 (lt)	2017-12-11
CA2626214A1 (en)	2007-05-03
SI2848258T1 (en)	2018-03-30
TWI626056B (zh)	2018-06-11
EP3332807A3 (en)	2018-06-20
RU2012133522A (ru)	2014-02-20
ES2662420T3 (es)	2018-04-06
IL190545A0 (en)	2008-11-03
TW201302220A (zh)	2013-01-16
EP1940465A2 (en)	2008-07-09
HK1204767A1 (zh)	2015-12-04
LTC2848258I2 (lt)	2019-08-12
DK1940465T3 (da)	2012-10-22
EP2848258A1 (en)	2015-03-18
PL1940465T3 (pl)	2013-01-31
IL258983A (en)	2018-06-28
NO20082344L (no)	2008-07-22
HUE036973T2 (hu)	2018-08-28
US20210147533A1 (en)	2021-05-20
EP3332807B1 (en)	2023-02-22
AU2006306280B2 (en)	2010-06-17
TWI537003B (zh)	2016-06-11
CN101291693B (zh)	2012-10-03
LTPA2018506I1 (lt)	2018-06-25
BRPI0617830A2 (pt)	2011-08-09
HK1121041A1 (en)	2009-04-17
LUC00078I2 (fr)	2018-08-14
NZ567222A (en)	2011-07-29
DK2848258T3 (en)	2018-03-19
NO345888B1 (no)	2021-09-27
EP2848258B1 (en)	2017-12-13
JP2013166757A (ja)	2013-08-29
CY2013046I2 (el)	2015-11-04
KR20170038131A (ko)	2017-04-05
US20240083997A1 (en)	2024-03-14
CY2018018I1 (el)	2018-12-12
US20170218063A1 (en)	2017-08-03
EP4218815A3 (en)	2024-03-27
NO345140B1 (no)	2020-10-12
JO2826B1 (en)	2014-09-15
TR201802449T4 (tr)	2018-03-21
EP2332577A1 (en)	2011-06-15
IL245387B (en)	2019-09-26
US20150322148A1 (en)	2015-11-12
IL277406A (en)	2020-11-30
ES2389110T3 (es)	2012-10-23
JP2009513645A (ja)	2009-04-02
LT2848258T (lt)	2018-02-26
JOP20140120B1 (ar)	2021-08-17
TNSN08189A1 (en)	2009-10-30

Publication	Publication Date	Title
HK1252316A1 (zh)	2019-05-24	IL-1β抗體的用途
IL234657A0 (en)	2014-11-30	Antibodies to p-cadherin
PT2343320T (pt)	2018-01-23	Anticorpos anti-gitr e as suas utilizações
IL222922A (en)	2015-07-30	Antibodies against neurophilin-1 and their use
IL191117A0 (en)	2008-12-29	Uses of anti-cd40 antibodies
IL188330A0 (en)	2008-04-13	Processes for the preparation of
EP1904101A4 (en)	2011-06-15	ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
EP1869192A4 (en)	2010-10-20	FRAME MIXTURE OF ANTIBODIES
EP1901733A4 (en)	2011-06-15	USE OF HUPERZINE FOR DISEASES
GB0517487D0 (en)	2005-10-05	Antibodies
HK1161122A1 (zh)	2012-08-24	的用途
DE602006000763D1 (de)	2008-05-08	Kissenkörper
EP1931370A4 (en)	2010-11-17	USE OF DES-ASPARTATE-ANGIOTENSIN I
EP1896047A4 (en)	2009-07-22	ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en)	2005-04-20	Antibodies
ITPD20050023U1 (it)	2006-10-13	Impedenzimetro corporeo
GB0512278D0 (en)	2005-07-27	Antibodies
GB0505054D0 (en)	2005-04-20	Antibodies
AT503708A3 (de)	2008-05-15	Fibrillationsarmer formkörper
GB0503190D0 (en)	2005-03-23	Human antibodies
GB0506945D0 (en)	2005-05-11	Human antibodies
GB0502201D0 (en)	2005-03-09	Human antibodies
ZA200802876B (en)	2009-09-30	Novel use of IL-1beta compounds
GB0519883D0 (en)	2005-11-09	Antibodies
TJ20050863A (en)	2007-06-05	The way of narcotism treatment